syndrome in extensive haemangioma of the tongue and lip in a newborn infant. 1

Thirdly, the sublingual goitres reported in the literature have not been uniformly defined in relation to the proportion of the thyroid gland within the thorax. Therefore, it is rather difficult to compare the sizes and the results of response to further management of sublingual goitres. For the last decade, we and others1 have chosen to refer to any goitre in which more than 50% of its mass is inferior to the thoracic inlet as sublingual.

LUC A MICHEL
JULIAN DONCIEK
Monto-Godinne University (UGL) Hospital,
Yvoir, B-5330, Belgium

Accepted 27 July 1998


Anaphylactoid reaction to hydroxyco- balamin with tolerance of cyanocobalamin

Sir,

A patient with an anaphylactoid reaction to hydroxyco- balamin but good tolerance of cyanocobalamin is described, which empha- sizes the uselessness of challenge tests in cases of allergic or pseudoallergic reactions.

A 33-year-old woman with a history of Crohn’s disease developed subacute combined degeneration of the spinal cord due to vitamin B12 deficiency. Replacement therapy with hydroxyco- balamin was established at a dose of 10 mg intramuscularly every month with no problems for more than a year. In the following 2 months, after a dose, the patient developed generalised urticaria and angioedema with involvement of the upper airway. Prick and intradermal tests performed with 5 mg/ml and 100 μg/ml of hydroxyco- balamin, respectively, were negative. Under in-hospital observation the patient was given 2500 μg of hydroxyco- balamin by the intra- muscular route; 20 min later, she experienced pruritus on her palms, shortly followed by generalised urticaria, prominent lip and palpebral oedema, hoarseness and chest tightness. The patient was treated with epine- phrine, methylprednisolone and chlorphen- iramine with total recovery in 2 hours. A challenge test with benzyal alcohol, added as preservative, was carried out with no reac- tion. On the basis that the neurologic manifestations would progress without ade- quate replacement therapy, a desensitiza- tion protocol was developed. Increasing doses of hydroxyco- balamin, beginning with 0.05 μg, were administered every 15 min by the intramuscular route. Ten minutes after the injection of 125 μg of hydroxyco- balamin, respectively, negative, of the same allergic reaction appeared. Premedica- tion with antihistamines did not provide reli- ably effective protection from the hydroxyco- balamin-induced reaction in the patient. However, intramuscular challenge tests with hydroxyco- balamin up to 10 mg, per- formed on three different occasions, were fol- lowed by no reaction. Subsequently, the patient receives 10 mg of cyanocobalamin monthly without problems.

Cobalamin is an organometallic vitamin which cannot be synthesised in the human body and is supplied in the diet. The minimum daily requirement is about 2.5 μg. In patients with disease of the distal small intestine such as Crohn’s disease, cobalamin deficieny may develop. In order to avoid clinical features of cobalamin deficieny, especially neurologic manifestations, replace- ment therapy is suggested. Because oral absorption is inadequate, replacement must be administered parenterally. The vitamin preparations which are used therapeutically are cyanocobalamin and hydroxyco- balamin (both also called vitamin B12) given intra- muscularly at monthly periods and main- tained indefinitely. Allergic reactions to vita- min B12 are rare but can be observed even after several years of treatment.1 James and Warin reported one patient with dyspnoea and urticaria in the course of a treatment with cyanocobalamin and hydroxyco- balamin in which specific IgE could not be showed, sug- gesting an anaphylactoid reaction rather than a real allergic mechanism.2 Recognising that a reaction is caused by direct histamine release may be important since treatment can gener- ally be continued by lowering the dose of the drug. In the patient reported here, the imme- diate response obtained with low doses of hydroxyco- balamin (125 μg) on rechallenge, the tolerance of previous doses of this drug (sensitisation period), together with the perfect tolerance of therapeutic doses of cyanocobalamin suggests an allergic mech- anism even in the presence of negative skin tests. Even though the reaction developed only at or above a dose of 125 μg, it is difficult to explain this as an anaphylactoid mech- anism, since the capacity of hydroxyco- balamin and cyanocobalamin to induce direct release of histamine is quite similar. A reaction to an excipient rather than to the drug itself was ruled out because the only preservative in the formulation was benzyal alcohol (provided by the manufacturer) which was well tolerated by the patient on challenge. Up to now, positive skin tests with hydroxyco- balamin have been described in only two patients. Accordingly, cyanoco- balamin may be given as an alternative in patients with a history of systemic reactions to hydroxyco- balamin.

C VIDAL
Allergy Unit
A LORENZO
Division of Gastroenterology
Hospital de Comillas, Complejo Hospitalario
Universitario, Rúa Ramón Baldrich sn, 15706
Santiago de Compostela, Spain

Accepted 27 July 1998

1 Upwu CN, Gibbins FJ. Anaphylactie reaction to vitamin B12 appearing after several years of treatment. Lancet 1967;1:262.


Salvage angioplasty following failed thrombolysis

Sir,

Drs Mahy and Jennings are correct to point out the dilemmas facing physicians responsi- ble for the further management of patients with acute myocardial infarction and appar- ent failure to respond to thrombolytic therapy.1 The lack of evidence supporting any particular management strategy is surprising given that up to 50% of patients fail to respond to thrombolytic therapy in the first few hours and that persistent ST segment elevation following acute myocardial infarction (AMI) is clearly associated with poor outcome.2 Purcell et al demonstrated a mortality of 18.2% in unselected patients with AMI and <50% resolution of ST segment elevation in the worst lead 60 minutes after the initiation of thrombolytic therapy. A subtype3 of the INJECT trial revealed a mortality of 17.5% in patients with ≤30% resolution of the summed ST segment elevation in leads reflecting the infarct zone. Even though it is frequently stated that such electrocardiographic (ECG) features are not 100% sensitive or specific for persistent arte- riocclusion, the presence of such features must alert us to a patient who is at high risk of further adverse events. Salvage angioplasty has only been examined in one prospective randomised study against conservative therapy.1 Despite a statistically significant reduction in the incidence of death or severe heart failure, this strategy has not been widely adopted, nor examined in patients with angioplasty era. This is surprising, given that this study probably underestimated the benefit of salvage angioplasty for a number of reasons. Firstly, high-risk patients, including those with a previous myocardial infarction who are perhaps more likely to benefit from attempts to open a second vessel, were excluded. Secondly, patients in this trial were taken on for salvage angioplasty relatively late after the onset of chest pain. Thirdly, intra-aortic balloon counterpulsation was rarely used, but is now known to reduce the risk of arterial occlusion following salvage angioplasty.4 Fourthly, the trial was performed without modern platelet inhibitors, such as abciximab (Reopro®). These agents have been shown to be beneficial in high-risk angioplasty without increased risk of haemorrhage.5 Lastly, and most importantly, this trial was performed in the early 1990s before the modern coronary artery stent era. It is undoubtedly the case that the availability of coronary artery stents allows angioplasty in the context of AMI to be performed with greatly improved outcomes, and should go far so as to say that the results of the trials of immediate angioplasty following thrombo- lytic therapy, which universally demonstrated unfavourable outcomes with this strategy, have no relevance in the modern stent era. This is an area which commands further study. Our policy of performing salvage angi- oplasty in the context of <50% ST segment resolution in the worst lead 2 hours after the initial thrombolytic therapy, with a well- sup- posed favourable results, especially if the patient presents promptly, receives thromboly- sylis promptly and the 2-hour ECG is scupulously reviewed. Our experience is that this policy can reduce mortality from an expected 17–20% to 5%. Thus, patients with persistent ST elevation following thrombo- lytic therapy should be considered early for
coronary angiography with a view to salvage angioplasty. Some patients will have reperfused by the time of coronary angiography if the above ECG criteria are applied, but we believe that the potential benefits far outweigh the risks of an ‘unnecessary’ angiogram.

A G C SUTTON
M A D BELDER
Cardiothoracic Division, South Cleveland Hospital, Marton Road, Middlesbrough TS4 3BW, UK

Accepted 27 July 1998

Images in medicine

Foreign body aspiration

A 76-year-old woman with known squamous carcinoma of the post-cricoid region, previously treated with laryngopharyngectomy and radiotherapy, was referred to a tertiary hospital having aspirated her Blomsinger tracheo-oesophageal valve (size 10 mm, figure 1). Clinically she had a stridor, and was cyanosed, dyspnoeic and unconscious. Oxygen saturation was 85% on 60% inspired oxygen via a Venturi mask. Chest X-ray (figure 2) showed a massive left hydropneumothorax (pneumothorax was created by a previous aspiration) and the Blomsinger valve lodged at the right hilum. Fibre-optic bronchoscopy revealed the valve to be lodged in the right intermediate bronchus. When the valve was removed the patient rapidly improved, with an oxygen saturation of 98% on 40% inspired oxygen.

The anatomy of the bronchial tree is such that the right main bronchus is shorter and wider than the left, and it separates off from the vertical at about 25° compared to the left at 45°. This makes aspiration more common in the right lower and middle lobes.

Figure 1 Blomsinger tracheo-oesophageal valve

Figure 2 Chest X-ray

2 Purcell IF, Newall N, Farrer M. Change in ST segment elevation 60 minutes after thrombolytic initiation predicts clinical outcome as accurately as later changes. *Heart* 1997;78:465–71.

S P L MEGHJEE
Department of Anaesthesia, York District Hospital, York YO3 7HE, UK

EMMA THOMAS
Specialist Registrar in Oncology, Leeds General Infirmary, Leeds LS1 3EX, UK
Salvage angioplasty following failed thrombolysis.

A. G. Sutton and M. A. de Belder

doi: 10.1136/pgmj.74.877.702-a